Comparing lamivudine plus dolutegravir and bictegravir/emtricitabine/ tenofovir alafenamide in antiretroviral therapynaive HIV-infected patients: preliminary results from clinical practice

被引：0
|
作者：
Long, H. [1 ]
机构：
[1] Guiyang Publ Hlth Clin Ctr, Guiyang, Peoples R China
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
406
引用
收藏
页码：105 / 106
页数：2
相关论文
共 50 条
  • [21] Tenofovir alafenamide plus dolutegravir as a switch strategy in HIV-infected patients: a pilot randomized controlled trial
    Alavian, Golbarg
    Abbasian, Ladan
    Khalili, Hossein
    Alinaghi, Seyed Ahmad Seyed
    Hasannezhad, Malihe
    Ashtiani, Masoumeh Farrokh
    Manshadi, Seyed Ali Dehghan
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 31 (02) : 145 - 153
  • [22] Neuropsychiatric, clinical and laboratory changes in patients prospectively switching from elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide to bictegravir/emtricitabine/tenofovir alafenamide
    Tiraboschi, J.
    Prieto, P.
    Saumoy, M.
    Silva, A.
    Imaz, A.
    Scevola, S.
    Fernandez-Olivares, G.
    Navarro-Alcaraz, A.
    Piatti, C.
    Podzamczer, D.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 79 - 80
  • [23] Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV
    De Socio, Giuseppe Vittorio
    Tordi, Sara
    Altobelli, Debora
    Gidari, Anna
    Zoffoli, Anastasia
    Francisci, Daniela
    Wozniacka, Anna
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (24)
  • [24] Clinical efficacy, safety, and subjective experience based on ePRO in HIV-infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China
    Kong, Linghong
    Xie, Xiaoxin
    Fu, Yanhua
    Gan, Lin
    Yang, Xiaoyan
    Ma, Shujing
    Long, Hai
    IMMUNITY INFLAMMATION AND DISEASE, 2023, 11 (08)
  • [25] Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study
    Baldin, G.
    Ciccullo, A.
    Capetti, A.
    Rusconi, S.
    Sterrantino, G.
    Cossu, M. V.
    Giacomelli, A.
    Lagi, F.
    Latini, A.
    Bagella, P.
    De Luca, A.
    Di Giambenedetto, S.
    Madeddu, G.
    HIV MEDICINE, 2019, 20 (02) : 164 - 168
  • [26] Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects
    Smith, D. E.
    Chan, D. J.
    Maruszak, H.
    Jeganathan, S.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2011, 22 (04) : 228 - 230
  • [27] Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients
    Gutierrez-Lorenzo, Marta
    Rubio-Calvo, Daniel
    Urda-Romacho, Joaquin
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2021, 34 (04) : 315 - 319
  • [28] Effects of switching to dolutegravir/lamivudine from tenofovir alafenamide fumarate/emtricitabine/dolutegravir or abacavir/lamivudine/dolutegravir on body weight and lipid profile in Japanese people living with HIV
    Ikegaya, Kenichi
    Muramatsu, Takashi
    Sekiya, Ryoko
    Sekine, Yusuke
    Harada, Yuko
    Miyashita, Ryui
    Yamaguchi, Tomoko
    Ichiki, Akito
    Chikasawa, Yushi
    Bingo, Masato
    Yotsumoto, Mihoko
    Hagiwara, Takeshi
    Amano, Kagehiro
    Takeuchi, Hironori
    Kinai, Ei
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2025, 31 (02)
  • [29] Intermittent bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) maintains viral suppression in real life in controlled HIV-infected patients
    Sellem, B.
    Abdi, B.
    Peytavin, G.
    Tubiana, R.
    Valantin, M. -A.
    Seang, S.
    Schneider, L.
    Faycal, A.
    Soulie, C.
    Marcelin, A. -G.
    Katlama, C.
    Pourcher, V.
    Palich, R.
    HIV MEDICINE, 2021, 22 : 90 - 91
  • [30] Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients
    Labarga, Pablo
    Medrano, Jose
    Seclen, Eduardo
    Poveda, Eva
    Rodriguez-Novoa, Sonia
    Morello, Judit
    de Mendoza, Carmen
    Vispo, Eugenia
    Soriano, Vincent
    AIDS, 2010, 24 (05) : 777 - 779
12345